Overview

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

This study is a proof of concept, multi-center, randomized, double-blind, placebo-controlled, parallel-group phase 2 dose-ranging study of BI 655066/ABBV-066 (risankizumab), an IL-23 p19 antagonist monoclonal antibody, in patients with moderately to severely active Crohn's disease.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Collaborator:

Boehringer Ingelheim

Treatments:

Antibodies, Monoclonal